ANEBULO PHARMACEUTICALS INC (ANEB) Stock Analyst Earnings Estimates
NASDAQ:ANEB - Nasdaq - US0345691036 - Common Stock - Currency: USD
Full estimates are only available for subscribed users, you can see which data is available below.
Subscribed users also see more surprise data, now it is restricted to 4 quarters.
Examples of complete estimate data are available for MSFT and AAPL.
Registered users have access to more data. Please register or login for additional estimates and surprises .
| 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 | 2027 | 2028 | 2029 | 2030 | 2031 | ||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue YoY % growth | N/A | N/A | N/A | N/A 476.79% | N/A 62.22% | N/A 35.19% | N/A 22.57% | ||||||
| EBITDA YoY % growth | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | |
| EBIT YoY % growth | -170K | -3.61M -2,023.53% | -6.83M -89.20% | -11.78M -72.47% | -8.309M 29.47% | N/A -8.79% | N/A -155.52% | N/A 13.55% | N/A 230.72% | N/A 160.84% | N/A 61.02% | N/A 38.37% | |
| Operating Margin | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | |
| EPS YoY % growth | N/A | N/A | N/A 56.45% | -0.47 -70.66% | -0.32 31.91% | N/A -5.19% | N/A -96.97% | N/A -21.54% | N/A 175.95% | N/A 170.00% | N/A 62.35% | N/A 35.36% |
All data in USD
| Q3 / 25 | Q4 / 25 | |
|---|---|---|
| EPS Q2Q % growth | -0.05 15.00% | -0.05 -2.00% |
| Revenue Q2Q % growth | ||
| EBITDA Q2Q % growth | N/A | N/A |
| EBIT Q2Q % growth | -2.346M -40.96% | -2.346M -75.02% |
All data in USD
| Period | Reported | Estimate | Difference | Surprise |
|---|---|---|---|---|
| Q2 2025 Q2Q % growth | -0.09 18.18% | -0.08 | -0.01 | -10.29% |
| Q1 2025 Q2Q % growth | -0.08 20.00% | -0.05 | -0.03 | -56.86% |
| Q4 2024 Q2Q % growth | -0.05 50.00% | -0.13 | 0.08 | 62.44% |
| Q3 2024 Q2Q % growth | -0.06 45.45% | -0.12 | 0.06 | 50.15% |
| Q2 2024 Q2Q % growth | -0.11 26.67% | -0.10 | -0.01 | -7.84% |
| Q1 2024 Q2Q % growth | -0.10 9.09% | -0.12 | 0.02 | 15.97% |
| Q4 2023 Q2Q % growth | -0.10 | -0.11 | 0.01 | 11.41% |
| Q3 2023 Q2Q % growth | -0.11 -37.50% | -0.16 | 0.05 | 31.31% |
| Q2 2023 Q2Q % growth | -0.15 -200.00% | -0.11 | -0.04 | -33.69% |
| Q1 2023 Q2Q % growth | -0.11 | -0.11 | 0.00 | -2.71% |
| Q4 2022 Q2Q % growth | -0.10 28.57% | -0.08 | -0.02 | -30.72% |
| Q3 2022 Q2Q % growth | -0.08 88.41% | -0.05 | -0.03 | -56.86% |
| Q2 2022 Q2Q % growth | -0.05 | -0.06 | 0.01 | 18.30% |
| Q4 2021 Q2Q % growth | -0.14 | -0.03 | -0.11 | -357.52% |
| Q3 2021 Q2Q % growth | -0.69 | -0.07 | -0.62 | -866.39% |
| Q1 2021 Q2Q % growth | -0.69 | -0.04 | -0.65 | -1,591.18% |
| Period | Reported | Estimate | Difference | Surprise |
|---|
| Next Q (1 month) | Next Q (3 month) | Next Year (1 month) | Next Year (3 month) | |
|---|---|---|---|---|
| EPS | 37.5% | 37.5% | 0% | -50% |
| Revenue | N/A | N/A | N/A | N/A |